Inventaire - your friends and communities are your best library - Inventaire

Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.

Autor

Giancarlo Comi

Gavin Giovannoni

Per Soelberg Sørensen

publikované v: Multiple Sclerosis Journal

dátum vydania: 2017-08-01

hlavná téma: Skleróza multiplex, relapsing-remitting multiple sclerosis

Cites articles 9

Date

Názov

Autori

2016-12-14

Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine

Karl Bjørnar Alstadhaug
2015-12

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine

Sue Pavitt, Monica Marta
2012-11

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Hans-Peter Hartung, Gavin Giovannoni, Howard L. Weiner, Ivana Kovářová
2011-01-12

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study

Gavin Giovannoni, Per Soelberg Sørensen
2010-01-20

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

Per Soelberg Sørensen, Giancarlo Comi, Gavin Giovannoni
2010-02-04

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Lixin Zhang-Auberson, Ludwig Kappos, Peter Calabresi, Frauke Zipp, Krzysztof Selmaj, Robert Weissert, Ernst-Wilhelm Radue, Chris Polman, Reinhard Hohlfeld
2007-11-01

The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation
1996-02-01

The treatment of chronic progressive multiple sclerosis with cladribine
1992-10-01

Cladribine (2-chlorodeoxyadenosine)

Article - wd:Q50224622

Welcome to Inventaire

the library of your friends and communities

you are offline